Tillotts Pharma Expands Asacol® Distribution in China Through Partnership with Pioneer Pharma

Tillotts Pharma AG, a Swiss pharmaceutical company under Japan’s Zeria Group, has entered into an exclusive partnership with Pioneer Pharma (Hong Kong) Co., Ltd., part of Shanghai Pioneer Holding Ltd. The agreement grants Pioneer the exclusive rights to distribute and market Tillotts’ Asacol® Tablets 800mg across mainland China. Asacol® is a key first-line treatment for mild to moderate ulcerative colitis (UC), a form of inflammatory bowel disease (IBD).

Through this collaboration, Tillotts aims to expand the global reach of Asacol®, making the medication more accessible to patients affected by IBD. Pioneer will leverage its expertise in the Chinese healthcare market to promote and distribute the product, helping to address the increasing demand for effective treatments in the region.

This partnership is particularly significant given the rising prevalence of IBD in China. Over the past decade, the country has experienced a two- to three-fold increase in IBD cases, making it one of the most affected regions in Asia. By working together, Tillotts and Pioneer hope to improve access to treatment and enhance the quality of care for patients with UC in China.